Commercial Credit Report for Kidswell Bio Corp

CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals. Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue. We also offer solutions that can help ease private company financial risk assessment. Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively.

A partial report preview for Kidswell Bio Corp is shown below. Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database. To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

	Kidswell Bio Corp
3F, Kanayama Bldg., 1-2-12, Shinkawa
Phone: +81 362229547p:+81 362229547	CHUO-KU, TKY 104-0033 Japan	Ticker: 45844584

Business Summary

Kidswell Bio Corp, formerly Gene Techno Science Co Ltd, is a Japan-based company mainly engaged in the development of biopharmaceuticals. The biosimilar business is engaged in the research, development and provision of filgrastim biosimilar products and pegfilgrastim biosimilar products for cancer, darbepoetin alfa biosimilar products for renal diseases, and ranibizumab biosimilar products for eye diseases. The new biopharmaceutical business is engaged in the research and development of anti-RAMP2 antibodies for cancer and eye diseases, as well as new antibodies. The new biotechnology business is engaged in the development of regenerative medicine products that utilize intracardiac stem cells for pediatric congenital heart diseases, and regenerative medicine products that utilize dental pulp stem cells for cleft lip and palate and intestinal ganglion cell deficiency diseases, as well as the joint research business with universities.

Scores and Ratings

FRISK^® Score	Z'' Score	PAYCE^® Score	DBT Index	Moody's Rating	Fitch Rating	DBRS Rating
Yes	Yes	-	-	-	-	-

Financials, News and Filings

Latest Statement	Last Audit	News	SEC Filings	Bankruptcy Filings	Suit & Judgment Filings	Tax Lien Filings
12/31/2023	3/31/2023	Yes	-	-	-	-

Industries

SIC Code	Description
8731	Commercial physical and biological research
2834	Pharmaceutical preparations

Officers and Directors

Title	Name	Age	Title Date	Start Date
President, Chief Executive Officer, Chief Communication Officer, Executive Officer, Representative	ShinyaKurebayashi	46	6/29/2023	3/12/2019
Chief Operating Officer, Executive Officer, Chief Development Officer, Chief Director of Developmen	MasayukiKawakami		6/29/2023	4/1/2018
Executive Officer, Chief Administrative Officer, Chief Senior Director of Administration	YasuoSakae		6/29/2023	1/1/2019
3 additional Officers and Directors records available in full report.

General Information

Number of Employees:	41	(As of 3/31/2023)
Outstanding Shares:	38,934,520	(As of 3/19/2024)
Shareholders:	8,837
Stock Exchange:	TYO
Fax Number:	+81 362229548

SITE MAP | ABOUT US | DIRECTORY | STOCK QUOTE: CRMZ | SIGN IN